Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vitrolife AB's Revenue for the
three
months ended in Jun. 2026 was kr857 Mil. Vitrolife AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was kr691 Mil.
Hence, Vitrolife AB's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.24.
Vitrolife AB (CHIX:VITRs) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vitrolife AB Receivables Turnover Related Terms
Vitrolife AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VITRS vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Vitrolife AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (CHIX:VITRS) has a Receivables Turnover of 1.24 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vitrolife AB and its competitors. According to the industry distribution chart, Vitrolife AB ranks #461 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 56.8%.
Is Vitrolife AB's Receivables Turnover too high?
Vitrolife AB's current Receivables Turnover is 1.24. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Vitrolife AB's value of 1.24 is 77.5% below this industry median. Based on the distribution chart, Vitrolife AB ranks #461 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #461 out of 811 companies for Receivables Turnover. This places Vitrolife AB in the lower half of its industry. The industry median Receivables Turnover is 5.51. Vitrolife AB's value of 1.24 is 77.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current Receivables Turnover of 1.24 is 77.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Receivables Turnover is 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current Receivables Turnover of 1.24. The stock's GF Value™ is kr185.92, compared to a current price of kr105.75 — trading 43.1% below its estimated fair value. The current Receivables Turnover is 1.24 and 77.5% below the Medical Devices & Instruments industry median of 5.51. Vitrolife AB's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Receivables Turnover is 1.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr105.75 is trading 43.1% below its estimated GF Value™ of kr185.92.
Key valuation signals for CHIX:VITRS:
Receivables Turnover: 1.24
GF Value™: kr185.92 vs. price of kr105.75 (43.1% below fair value)
Industry Position: 77.5% below the Medical Devices & Instruments median (#461 of 811)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
77GF Score
Get the complete analysis for CHIX:VITRS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
